['Neuroblastic tumors include the neuroblastomas, ganglioneuroblastomas, and ganglioneuromas. Clinical behavior of these developmental malignancies varies from regression to aggressive growth with metastatic dissemination. Several clinical, histological, genetic, and biological features are associated with this diversity of clinical presentations. The calcium-sensing receptor (CaSR) is a G-protein coupled receptor with a key role in calcium homeostasis. We have previously reported that it is expressed in benign, differentiated neuroblastic tumors, but silenced by genetic and epigenetic events in unfavorable neuroblastomas. We have now analyzed three functionally relevant polymorphisms clustered at the signal transduction region of the CaSR (rs1801725, rs1042636 and rs1801726) to assess if genetic variants producing a less active receptor are associated with more aggressive disease course.', 'Polymorphisms were analyzed in DNA samples from 65 patients using specific Taqman Genotyping Assays.', 'Mildly inactivating variant rs1801725 was associated with clinical stage 4 (P\u200a=\u200a0.002) and the histological subgroup of undifferentiated neuroblastomas (P\u200a=\u200a0.046). Patients harboring this polymorphism had significantly lower overall (P\u200a=\u200a0.022) and event-free survival (P\u200a=\u200a0.01) rates than those who were homozygous for the most common allele among Caucasians. However, this single locus genotype was not independently associated with outcome in multivariate analyses. Conversely, the tri-locus haplotype TAC was independently associated with an increased risk of death in the entire cohort (Hazard Ratio\u200a=\u200a2.45; 95% Confidence Interval [1.14-5.29]; P\u200a=\u200a0.022) and also in patients diagnosed with neuroblastomas (Hazard Ratio\u200a=\u200a2.74; 95% Confidence Interval [1.20-6.25]; P\u200a=\u200a0.016).'] Are polymorphisms in the calcium-sensing receptor gene associated with clinical outcome of neuroblastoma?